Clinical Trial Update: A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days [Phase 1]

View source ↗

Summary

A Phase 1 study assessed safety, tolerability and pharmacokinetics of oral SRT2104 in healthy elderly subjects over 28 days. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscular Atrophy

Drugs mentioned

• SRT2104 (SRT2104)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atrophy, Muscular | Phase 1 | Status: COMPLETED